Imunon, Inc.

Contributing Author

Recent Articles by Imunon, Inc.

Jun-05	IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th IMNN GlobeNewswire
Jun-03	IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study IMNN GlobeNewswire
Jun-02	IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS IMNN GlobeNewswire
May-28	IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules IMNN GlobeNewswire
May-27	IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 IMNN GlobeNewswire
May-23	IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules IMNN GlobeNewswire
May-23	IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer IMNN GlobeNewswire
May-22	IMUNON Announces Withdrawal of Form S-1 Registration Statement IMNN GlobeNewswire
May-15	IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 IMNN GlobeNewswire
May-12	IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update IMNN GlobeNewswire
May-08	IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer IMNN GlobeNewswire
May-06	IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology IMNN GlobeNewswire
May-05	IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 IMNN GlobeNewswire